NCT05360238

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Terminated Phase 1, PHASE2 Last updated 22 July 2024

What this trial tests

Phase 1, PHASE2 trial testing MB-106 in Follicular B-cell Non-Hodgkin's Lymphoma in 20 participants. Terminated before completion.

Timeline

24 May 2022

Primary endpoint
12 April 2024

12 April 2024

Quick facts

Lead sponsor	Mustang Bio
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	24 May 2022
Primary completion	12 April 2024
Estimated completion	12 April 2024
Sites	6 locations across United States

Drugs / interventions tested

• MB-106 — full drug profile →

Conditions studied

• Follicular B-cell Non-Hodgkin's Lymphoma — all drugs for Follicular B-cell Non-Hodgkin's Lymphoma →
• Mantle Cell Lymphoma Recurrent — all drugs for Mantle Cell Lymphoma Recurrent →
• Mantle Cell Lymphoma Refractory — all drugs for Mantle Cell Lymphoma Refractory →
• Small Lymphocytic Lymphoma, Relapsed — all drugs for Small Lymphocytic Lymphoma, Relapsed →

Sponsor

Mustang Bio — full company profile →

Who can join

18 and older, any sex, with Follicular B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. CAR T-Cell therapy for the management of mantle cell lymphoma.
   Huang Z, Chavda VP, Bezbaruah R, Dhamne H, et al · · 2023 · cited 35× · PMID 37004047 · DOI 10.1186/s12943-023-01755-5
2. Managing Waldenström's macroglobulinemia with BTK inhibitors.
   Buske C, Jurczak W, Salem JE, Dimopoulos MA. · · 2023 · cited 26× · PMID 36402930 · DOI 10.1038/s41375-022-01732-9
3. Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.
   Jain N, Mamgain M, Chowdhury SM, Jindal U, et al · · 2023 · cited 19× · PMID 37626420 · DOI 10.1186/s13045-023-01496-4
4. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma.
   Arun Kumar S, Gao J, Patel SA. · · 2023 · cited 12× · PMID 37672954 · DOI 10.1016/j.leukres.2023.107385
5. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.
   Pang Y, Ghosh N. · · 2024 · cited 2× · PMID 38711850 · DOI 10.3389/fonc.2024.1396395
6. Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology.
   Ershova A, Goldaeva A, Staliarova A, Bulatov E, et al · · 2025 · cited 1× · PMID 40726984 · DOI 10.3389/fimmu.2025.1592377
7. A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
   Kaedbey R, Forward N, Sehn LH, Shafey M, et al · · 2022 · PMID 36290837 · DOI 10.3390/curroncol29100560